Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report

Anti-angiogenics have become an important part of the treatment of several types of tumours such as ovarian, breast, lung and colorectal cancer. Necrotising fasciitis has been reported with bevacizumab but no cases have been reported with aflibercept, ramucirumab or regorafenib in patients with colo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the Royal College of Surgeons of England 2017-11, Vol.99 (8), p.e225-e226
Hauptverfasser:	Gonzaga-López, A, Muñoz-Rodriguez, J, Ruiz-Casado, A
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Camptothecin - adverse effects Camptothecin - analogs & derivatives Camptothecin - therapeutic use Cancer therapies Cardiac arrhythmia Case reports Chemotherapy Colorectal cancer Colorectal Neoplasms - complications Colorectal Neoplasms - drug therapy Fasciitis, Necrotizing Fatal Outcome Fever Fluorouracil - adverse effects Fluorouracil - therapeutic use Fournier Gangrene Gangrene Humans Hypertension Immunotherapy Infections Leucovorin - adverse effects Leucovorin - therapeutic use Liver Male Metastasis Middle Aged Monoclonal antibodies Mortality Necrotizing fasciitis Online Case Report Patients Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - therapeutic use Substance abuse treatment Targeted cancer therapy Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Anti-angiogenics have become an important part of the treatment of several types of tumours such as ovarian, breast, lung and colorectal cancer. Necrotising fasciitis has been reported with bevacizumab but no cases have been reported with aflibercept, ramucirumab or regorafenib in patients with colorectal cancer. Necrotising fasciitis is a rare complication affecting one in 5000 bevacizumab users. We report the case of a 64-year-old man with stage IV rectosigmoid cancer under treatment with folinic acid, fluorouracil and irinotecan (FOLFIRI) and aflibercept, who developed a Fournier's gangrene.
ISSN:	0035-8843 1478-7083
DOI:	10.1308/rcsann.2017.0143